Fry joined us for an exclusive interview, discussing lessons learned during the pandemic, some key ways to address physician burnout and much more. 

The virtual reality training sessions were designed to feature "the same sights, sound and sensations a surgeon would encounter during real procedures." 

Learn more about the late-breaking studies presented at ACC.22 in Washington, D.C. 

Drug-coated balloons were associated with a lower risk of bleeding after PCI than drug-eluting stents, the study's authors reported. 

Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.

Adam Greenbaum, MD, co-director of the Structural Heart and Valve Center at Emory University Hospital Midtown in Atlanta, explains details from the late-breaking CLASP TR trial at ACC.22.

Several late-breaking clinical trials at ACC.22 will likely impact clinical practice. Below are summaries of a few key trials and their takeaways for interventional cardiology and structural heart interventions. 

The study's authors examined data from the DANAMI-3 trial, focusing on such outcomes as all-cause mortality, recurrent MI and target vessel revascularization.